Document is current
Any future updates will be listed below
-
Authors
Souliotis, Kyriakos https://orcid.org/0000-0003-1624-9444
Golna, Christina
Golnas, Paul
Markakis, Ioannis-Anestis
Makras, Polyzois
-
Funding
Funding for this research was provided by:
UCB/AMGEN (4400428049)
- License Information
-
More Information
Article History
Received: 18 March 2022
Accepted: 13 June 2022
First Online: 11 July 2022
Declarations
:
: The authors declare no other conflict of interest relative to this work. Souliotis K has received advisory boards’ fees from Boehringer Ingelheim, Βristol Myers Squibb and Pfizer. Makras P has received lecture fees/advisory boards from Amgen, ELPEN, Farmaserv, Galenica, Genesis, Lilly, Pfizer, Rapharm, Takeda, UCB Pharma, UniPharma, and VIANEX; research grant from Amgen.
: This is a modelling study and did not acquire nor use or store any patient data. Ethics committee approval and consent were not required.
: Our study is a stochastic modelling study and did not involve any human or animal participants. The study did not acquire nor use or store any human or animal data.
